Recent oncolytic virotherapy clinical trials outline a roadmap for the treatment of high-grade glioma.

Recent oncolytic virotherapy clinical trials outline a roadmap for the treatment of high-grade glioma.
复制标题

DOI:
10.1093/noajnl/vdad081
复制
发表时间:
2023-01
期刊:
NEURO-ONCOLOGY ADVANCES
影响因子:
--
通讯作者:
Friedman, Gregory K.
Friedman, Gregory K.
中科院分区:
其他
文献类型:
--
作者:
Bernstock, Joshua D.;Blitz, Sarah E.;Hoffman, Samantha E.;Gerstl, Jakob V. E.;Chiocca, E. Antonio;Friedman, Gregory K.

文献摘要

参考文献

被引文献

相似文献

成人和儿童高级别胶质瘤(HGGs)是中枢神经系统的侵袭性癌症,临床预后不佳。标准放疗和化疗对HGGs的疗效有限,这促使人们加速研究溶瘤病毒(OV)等新疗法。以OV为中心的治疗通过以肿瘤溶解和刺激抗肿瘤免疫反应为中心的混合机制起作用。最近三项使用单纯疱疹病毒-1和腺病毒为基础的溶瘤病毒治疗的临床试验不仅证明了OV的安全性和有效性,而且还证明了增加OV反应潜力的新剂量策略。考虑到这些近期的试验,本文提出了溶瘤免疫病毒治疗在成人和儿童HGG的未来临床试验的路线图,以及与试验内和试验之间评估OV疗效相关的持续障碍。
Adult and pediatric high-grade gliomas (HGGs) are aggressive cancers of the central nervous system that confer dismal clinical prognoses. Standard radiation and chemotherapy have demonstrated only limited efficacy in HGGs, motivating the accelerated investigation of novel modalities such as oncolytic virus (OV) therapies. OV centered therapies work through a mixed mechanism centered on oncolysis and the stimulation of an antitumor immune response. Three recent clinical trials utilizing herpes simplex virus-1 and adenovirus-based oncolytic virotherapy demonstrated not only the safety and efficacy of OVs but also novel dosing strategies that augment OV response potential. Considering these recent trials, herein we present a roadmap for future clinical trials of oncolytic immunovirotherapy in both adult and pediatric HGG, as well as persistent roadblocks related to the assessment of OV efficacy within and between trials.
DOI: 10.1158/1078-0432.ccr-22-1382
发表时间: 2022-12-15
期刊: Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子: --
作者:
通讯作者: --
DOI: 10.1200/jco.2017.75.8219
发表时间: 2018-05-10
影响因子: 45.3
作者:
Lang, Frederick F.;Conrad, Charles;Fueyo, Juan
通讯作者: Fueyo, Juan
DOI: 10.1038/sj.clpt.6100134
发表时间: 2007-04-01
影响因子: 6.7
作者:
Abdel-Rahman, S. M.;Reed, M. D.;Kearns, G. L.
通讯作者: Kearns, G. L.
DOI: 10.1080/2162402x.2019.1678921
发表时间: 2019-10-20
期刊: ONCOIMMUNOLOGY
影响因子: 7.2
作者:
Bernstock, Joshua D.;Vicario, Nunzio;Friedman, Gregory K.
通讯作者: Friedman, Gregory K.
DOI: 10.1016/j.pharmthera.2022.108193
发表时间: 2022-11
影响因子: 13.5
作者:
Ghajar-Rahimi, Gelare;Kang, Kyung-Don;Totsch, Stacie K.;Gary, Sam;Rocco, Abbey;Blitz, Sarah;Kachurak, Kara;Chambers, M. R.;Li, Rong;Beierle, Elizabeth A.;Bag, Asim;Johnston, James M.;Markert, James M.;Bernstock, Joshua D.;Friedman, Gregory K.
通讯作者: Friedman, Gregory K.